Cogent Biosciences

1. CGT4859 3 Inhibitor interim2026CGT4859 3 Inhibitor interim, 2026, notable
2. CGT1815 pan-KRAS Inhibitor IND filing2026CGT1815 pan-KRAS Inhibitor IND filing, 2026, notable
3. CGT1145 IND filing2026CGT1145 IND filing, 2026, notable
4. Bezuclastinib commercial launch2H 2026Bezuclastinib commercial launch, 2H 2026, routine
5. Bezuclastinib + sunitinib GIST PDUFANov 30, 2026Bezuclastinib + sunitinib GIST PDUFA, Nov 30, 2026, thesis-defining
6. Bezuclastinib NonAdvSM PDUFA dateDec 30, 2026Bezuclastinib NonAdvSM PDUFA date, Dec 30, 2026, thesis-defining
7. 1L exon 9 GIST extension20271L exon 9 GIST extension, 2027, notable
8. Bezuclastinib AdvSM PDUFA dateJun 29, 2027Bezuclastinib AdvSM PDUFA date, Jun 29, 2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.